ClinicalTrials.gg
RecruitingNCT04496479Updated Aug 8, 2025

Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes

A Phase 2 interventional study of LYG-LIV0001 in End Stage Liver Disease, sponsored by LyGenesis, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-08-08.

Sponsored by LyGenesis, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in End Stage Liver Disease with a site in United States — 9 open to participants now, 15 under way, none of them phase 3. End Stage Liver Disease · United States.

Planned enrollment
40th of 48
12 · median 64
Started
2022
with 9 others
Phase 2
4 of 66
1 open now
Primary completion
2027-08
later than 9 of 14 live
Registered
45th of 66
by date

Among the 66 studies in End Stage Liver Disease with a site in United States, this one is the 40th largest by planned enrollment of the 48 interventional ones that give a count, is one of 10 that started in 2022, is one of 4 in phase 2, reaches primary completion later than 9 of the 14 other live ones, and was the 45th registered.

End Stage Liver Disease

155 studies on the registry are indexed under End Stage Liver Disease; 31 are open to participants now.

Browse End Stage Liver Disease studies →

Open to participants now

9 of the 66 studies in End Stage Liver Disease with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 End Stage Liver Disease studies recruiting now, 14 (67%) set no upper age limit and 6 (29%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in End Stage Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This Phase 2a clinical trial is a dose escalation study of the safety, tolerability, and efficacy of hepatocyte transplantation into lymph nodes via endoscopic ultrasound among subjects with end-stage liver disease.

Read the detailed description

This safety, tolerability, and efficacy study includes an open-label dose-escalation phase for up to 12 subjects with end-stage liver disease (ESLD).

03

Conditions studied

  • End Stage Liver Disease

Keywords

  • Allogeneic
  • Organogenesis
  • Hepatocyte
  • Transplantation
  • Liver Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have read, understood, and signed the form (ICF).
  2. Adults of either gender and ages 18 to 70 years old with a diagnosis of ESLD due to alcohol, chronic virus (HBV) and/or virus (HCV) infections, hepatitis, primary sclerosis cholangitis, primary biliary cirrhosis (cholangitis), cirrhosis as the result of Wilson disease, hemochromatosis, sarcoidosis and alpha 1 antitrypsin deficiency, cryptogenic cirrhosis, and nonalcoholic steatohepatitis cirrhosis with a MELD-Na score >10 and \<25 at screening.
  3. Subjects must have a (BMI) \<35.
  4. Subjects with HCV associated ESLD must have been treated and demonstrate 24 weeks of negative HCV ribonucleic acid (RNA).
  5. Subjects with HBV must be on stable therapy for 6 months and have HBV deoxyribonucleic acid \<500 c/mL.
  6. Women of (WOCBP) or sexual partners of male subjects who are WOCBP must be able and willing to use at least 1 highly effective method of during the study and for 1 month after the last study visit. A female subject is considered to be a WOCBP after menarche and until she is in a state for 12 months or otherwise permanently sterile (for which acceptable methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy; HMA, 2014). For the definition and list of highly effective methods of contraception, see Appendix 1.
  7. Has stable control of portal hypertension and upper gastrointestinal bleeding with medical therapy and/or endoscopic therapy.
  8. If the subject has undergone a TIPS procedure for the clinical management of portal hypertension, they must be stable after the successful TIPS procedure, and not experiencing serious complications from the TIPS procedure itself (e.g., infection and intractable hepatic encephalopathy).
  9. Has blood urea nitrogen (BUN) \<80 mg/dL.
  10. Has an estimated (eGFR) ≥45 mL/min/1.73 m2.
  11. Agrees to avoid alcohol consumption during the study.
  12. Is willing and able to comply with all requirements of the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Has primary hepatic neoplasms (hepatocellular carcinoma and cholangiocarcinoma).
  2. Has active and/or uncontrolled severe infections requiring hospitalization and prolonged antimicrobial therapy.
  3. Has severe coagulopathy ( [INR] >2, and/or count \<50,000/μL).
  4. Has psychiatric and/or social issues that could lead to noncompliance.
  5. Has an extrahepatic neoplastic disease requiring active chemotherapy, immunotherapy, and/or surgical resection.
  6. Has previously treated neoplastic disease with less than a 2-year cancer free period.
  7. Pregnant and lactating women should not be in the study.
  8. Known to human serum albumin.
  9. Subjects with uncontrolled hypertension (defined as a diastolic blood pressure of 110 mmHg or higher).
  10. Has recurrent/intractable ascites to diuretics and requiring periodic large volume paracentesis.
  11. Has primary alcoholic liver disease and has not demonstrated abstinence for at least 24 weeks (6 months) prior to enrollment while attending mandatory rehab programs (e.g., Alcoholics Anonymous) and psychotherapy.
  12. Has grade 3 esophageal varices requiring the continuous use of propranolol and cannot afford to have this medication withheld and/or discontinued.
  13. Has a Child-Turcotte-Pugh (CTP) Class of C.
  14. Is receiving or plans to receive treatment with another product or device.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    LYG-LIV0001

    Open label group of subjects with end stage liver disease receiving increasing doses of the experimental therapy.

    Biological: LYG-LIV0001

Interventions

  • BiologicalLYG-LIV0001

    Allogenic hepatocytes suspended in a buffered cell preservation solution with increasing number of lymph nodes being transplanted for the dose escalation. Subjects will also receive immune suppression, including tacrolimus capsules to follow the dose prescribed by the investigator as well as a short course of prednisone.

06

What researchers measure

Primary outcomes

  1. Dosage Selection

    The primary objective of the dose escalation is to confirm the optimal dose of transplanted hepatocytes to safely achieve adequate allogeneic hepatocyte (AH) engraftment

    Time frame: Week 12

  2. Safety of Engraftment of Hepatocytes in to Lymph Nodes

    The primary safety objective of the dose escalation is to determine whether AH engraftments into the periduodenal lymph nodes in subjects with end-stage liver disease is safe as determined by the number/severity of adverse events

    Time frame: Week 12

  3. Efficacy of Engraftment of Hepatocytes in to Lymph Nodes

    The primary efficacy objective of the dose escalation is to determine whether AH engraftments into the periduodenal lymph nodes in subjects with end-stage liver disease is efficacious in addressing some of the signs and symptoms of end-stage liver disease

    Time frame: Week 12

Secondary outcomes

  1. Effectiveness of Selected Treatment to Modify the Liver Function Panel

    Evaluate the effectiveness of hepatocyte transplants in modifying the liver function panel (total serum bilirubin, ammonia, prothrombin time, international normalized ratio, sodium, blood urea nitrogen, and creatinine) as measured through changes in laboratory biomarkers caused by end-stage liver disease

    Time frame: Week 52

Other outcomes

  1. Change from Baseline in Ascities/Sarcopenia

    Changes from baseline in ascities/sarcopenia as measured by Computerized Tomography (CT) Scan

    Time frame: Week 52

  2. Change from Baseline in Lean Body Mass

    Changes from baseline in lean body mass as measured by Skinfold Testing, Bioelectrical Impedance Analysis, or DexaScan

    Time frame: Week 52

  3. Change from Baseline in Liver Reserve

    Changes from baseline in liver reserve as measured through the Disease Severity Index

    Time frame: Week 52

  4. Change from Baseline in Hepatic Function

    Changes from baseline in hepatic function as measured through the HepQuant SHUNT Testing (assessing liver function in chronic liver disease)

    Time frame: Week 52

  5. Change from Baseline in Quality of Life

    Changes from baseline in quality of life as measured through the SF-36 (total score and sub-scale scores) Questionnaire

    Time frame: Week 52

  6. Change from Baseline in Fatigue

    Changes from baseline in fatigue as measured through the Neuro-QOL Short Form (Fatigue Scale)

    Time frame: Week 52

  7. Change from Baseline in Neuropsychological Status

    Changes from baseline in neuropsychological status as measured by the Repeatable Battery of Neuropsychological Status (RBANS) test

    Time frame: Week 52

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2022 (actual). Primary completion is estimated for Aug 2027, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2020
First posted
Aug 3, 2020
StartActual
Mar 11, 2022
Primary completionEst.
Aug 20, 2027
CompletionEst.
Dec 30, 2027
Last update
Aug 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04496479
Lead sponsor
LyGenesis, Inc.
Responsible party
Sponsor
First posted
Aug 3, 2020
Start date
Mar 11, 2022
Primary completion
Aug 20, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Aug 8, 2025

Study contacts

Paulo Fontes, MD
Contact
fontesp@lygenesis.com
412-860-3599
Paulo Fontes, MD
study chair · LyGenesis, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion